Form 8-K - Current report:
SEC Accession No. 0001651308-25-000012
Filing Date
2025-01-13
Accepted
2025-01-13 17:02:00
Documents
13
Period of Report
2025-01-13
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K bgne-20250113.htm   iXBRL 8-K 37611
  Complete submission text file 0001651308-25-000012.txt   161759

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT bgne-20250113.xsd EX-101.SCH 1782
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT bgne-20250113_lab.xml EX-101.LAB 21545
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT bgne-20250113_pre.xml EX-101.PRE 12484
15 EXTRACTED XBRL INSTANCE DOCUMENT bgne-20250113_htm.xml XML 2865
Mailing Address C/O MOURANT GOVERNANCE SERVICES (CAYMAN) 94 SOLARIS AVENUE, CAMANA BAY GRAND CAYMAN E9 KY1-1108
Business Address C/O MOURANT GOVERNANCE SERVICES (CAYMAN) 94 SOLARIS AVENUE, CAMANA BAY GRAND CAYMAN E9 KY1-1108 13459494123
BeiGene, Ltd. (Filer) CIK: 0001651308 (see all company filings)

EIN.: 981209416 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37686 | Film No.: 25526956
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)